HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

A long-term study of hemophilic arthropathy of the knee joint on a program of Factor VIII replacement given at time of each hemarthrosis.

Abstract
Because there is little available data to demonstrate whether demand therapy is adequate to prevent progression of hemophilic arthropathy, a cohort of 64 patients with severe Hemophilia A (Factor VIII level less than 1%) and no inhibitor were studied with respect to the progression of knee arthropathy over a period of 6 years. Both degree of disease in flexion and extension and progression of disease were rated on an arbitrary scale. At the outset of the study, the majority of knees were either not restricted or mildly restricted as to motion. Of those knees that were not restricted at the outset, 96% remained not restricted. Of the knees that were mildly restricted, only 58% remained stable or improved over the 6 years, and of the knees that were moderately to severely restricted, 75% improved or remained stable. It thus appears that a demand therapy program can maintain normal range of motion in a knee joint. However, if the patient's joint has progressed to mild disease, the ability to maintain or improve the joint with demand therapy appears to be decreased.
AuthorsD B Brettler, A D Forsberg, F D O'Connell, A I Cederbaum, A K Chaitman, P H Levine
JournalAmerican journal of hematology (Am J Hematol) Vol. 18 Issue 1 Pg. 13-8 (Jan 1985) ISSN: 0361-8609 [Print] UNITED STATES
PMID3917602 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Factor VIII
Topics
  • Adult
  • Factor VIII (therapeutic use)
  • Hemarthrosis (complications, drug therapy, physiopathology)
  • Hemophilia A (complications)
  • Humans
  • Joint Diseases (complications)
  • Knee Joint
  • Long-Term Care
  • Middle Aged
  • Motion

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password:


Research Interface PRO additionally includes drill-down to evidence, articles by author, export to Excel, FDA Link and mobile subscription:
1 year subscription, $490.00 USD